575 related articles for article (PubMed ID: 22438441)
1. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
2. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
3. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
5. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
7. Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.
An YY; Kim SH; Kang BJ; Lee AW
J Korean Med Sci; 2015 Jun; 30(6):808-15. PubMed ID: 26028936
[TBL] [Abstract][Full Text] [Related]
8. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
10. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
11. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
Pahk K; Kim S; Choe JG
Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
[TBL] [Abstract][Full Text] [Related]
12. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer.
Park SH; Moon WK; Cho N; Chang JM; Im SA; Park IA; Kang KW; Han W; Noh DY
Eur Radiol; 2012 Jan; 22(1):18-25. PubMed ID: 21845462
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer.
Baysal H; Serdaroglu AY; Ozemir IA; Baysal B; Gungor S; Erol CI; Ozsoy MS; Ekinci O; Alimoglu O
J Surg Res; 2022 Oct; 278():223-232. PubMed ID: 35636197
[TBL] [Abstract][Full Text] [Related]
15. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
17. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
[TBL] [Abstract][Full Text] [Related]
18. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
19. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
Pengel KE; Koolen BB; Loo CE; Vogel WV; Wesseling J; Lips EH; Rutgers EJ; Valdés Olmos RA; Vrancken Peeters MJ; Rodenhuis S; Gilhuijs KG
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1515-24. PubMed ID: 24777490
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]